Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
about
A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adultsHIV infection of macrophages is enhanced in the presence of increased expression of CD163 induced by substance PInvolvement of substance P and the NK-1 receptor in human pathology.The immunological contribution to heterotopic ossification disorders.Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.The Selective Serotonin Reuptake Inhibitor Citalopram Decreases Human Immunodeficiency Virus Receptor and Coreceptor Expression in Immune Cells.Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIVSubstance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor.Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor.The Therapeutic Potential of Targeting Substance P/NK-1R Interactions in Inflammatory CNS DisordersSafety of neurokinin-1 receptor antagonists.Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.Substance P-mediated chemokine production promotes monocyte migration.Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults.Neurokinin-1 receptor antagonists: A new revolution in antiretroviral treatment?Detection of the full-length transcript variant for neurokinin-1 receptor in human whole blood associated with enhanced reinforcement of clot by substance-P.
P2860
Q28740565-E0A810CB-E550-4B1B-89D9-A0BA561AA38EQ33750864-CD65D165-6462-4796-8A8B-F1F408DD6F9CQ34413850-3AB08EC1-0224-45DF-9A6A-5EC5F33465FEQ35563973-FBB96A00-4411-43D8-939C-A457D16822A5Q35755634-11345BCB-FEED-41DA-9B48-56906343F60EQ36889342-389FE17C-C9D9-475B-A1B2-935485278DF6Q36937565-60A001E1-C1E2-4A7C-9781-AC7BFA7E66D0Q37034775-10CADEF4-5D07-4AF1-B373-05E26BA2A1F4Q37340453-15529453-A6E6-450E-A90E-4549712D9741Q37553389-0388CDAC-BAFB-4E8C-8E92-0891E350B2ECQ38109245-F414C235-34F7-4C4F-846C-84D8CE42B9CBQ38816965-188FAE5F-2518-4065-9196-277730440528Q40268840-EDD5322C-ED46-43D5-856A-E66CDAA49A5FQ41924104-F43304B5-3BB7-465C-B79B-00A96AE65213Q41989513-1402C864-2B08-4FD9-ABC9-52BAFEDA5284Q54340638-A0E0AC26-63A9-4FB9-AA8D-96EF4661E3FC
P2860
Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Anti-HIV-1 activity of the neu ...... ns with other antiretrovirals.
@ast
Anti-HIV-1 activity of the neu ...... ns with other antiretrovirals.
@en
type
label
Anti-HIV-1 activity of the neu ...... ns with other antiretrovirals.
@ast
Anti-HIV-1 activity of the neu ...... ns with other antiretrovirals.
@en
prefLabel
Anti-HIV-1 activity of the neu ...... ns with other antiretrovirals.
@ast
Anti-HIV-1 activity of the neu ...... ns with other antiretrovirals.
@en
P2093
P2860
P1433
P1476
Anti-HIV-1 activity of the neu ...... ns with other antiretrovirals.
@en
P2093
Dmitry A Moshkoff
Florin Tuluc
John Meshki
Lequan T Nguyen
Steven D Douglas
P2860
P304
P356
10.1097/QAD.0B013E3283405C33
P407
P577
2010-11-01T00:00:00Z